Continue Reading With Our 7-Day Free Trial
Boston Scientific (NYSE:BSX) spent the weekend putting forward what looked, at first glance, like a clinically solid case for Watchman FLX. The device met its main efficacy goal against modern blood thinners, delivered a meaningful reduction in non-procedural bleeding, and strengthened the argument that left atrial appendage closure can be more than a fallback option for atrial fibrillation patients.
Yet the stock still fell about 9%, because the market zoomed in on one uncomfortable detail buried inside the data: ischemic stroke came in at 3.2% versus 2.0% for blood thinners. That number instantly became the headline.
The real question now is whether investors correctly identified a meaningful problem, or whether they reacted to a single nuance while ignoring the broader clinical and commercial setup.
The Entire Selloff Revolved Around One Number, Not The Whole Trial
The easiest way to understand the market reaction is to recognize that this was not a broad rejection of the Watchman FLX dataset. The trial met its prespecified non-inferiority endpoint and showed a clear reduction in bleeding, which was one of the most commercially important things Boston Scientific needed to prove.
In other words, this was not a failed study. It was a study that largely worked, but came attached to one detail that was easy to isolate and hard to ignore.
The 3.2% vs 2.0% stroke rate became the market’s focal point because it was simple, intuitive, and emotionally powerful. Once that happened, everything else in the dataset got pushed to the side.
That is often how these healthcare selloffs work. A nuanced body of evidence gets boiled down into one scary statistic, and the stock trades on that fear before investors fully digest where it sits inside the full trial design.
Management and physicians, however, were not presenting the result as a disaster. They pointed to low overall event rates, a very small annualized gap, and the fact that the study was not powered at three years to make ischemic stroke the defining conclusion.
That does not make the concern irrelevant. But it does show that the stock’s reaction was driven less by the totality of evidence and more by the most emotionally combustible detail.
What Wall Street Punished Was Not Failure, But “Good Data That Wasn’t Perfect”
The hardest thing for a stock at a premium valuation is not bad news. Sometimes it is data that is good enough, but not clean enough to force a rerating upward.
That seems much closer to what happened here. Analysts did not dismiss the stroke imbalance, but they framed the result as supportive of continued Watchman adoption and long-term growth.
This is not the same as saying the thesis is broken. It is closer to saying the base case survived, while the upside scenario got pushed out.
That distinction matters because Boston Scientific had already become a stock where expectations were doing a lot of the heavy lifting. Investors were looking for a clear “home run”, not a nuanced outcome.
When the dataset landed, the market did not see a transformational catalyst. It saw validation, but not enough to justify paying the same aggressive multiple for faster adoption.
In that sense, the selloff was as much about valuation psychology as clinical interpretation. The stock was not punished because Watchman stopped mattering. It was punished because the narrative shifted from “explosive upside” to “steady execution.”
The Market May Have Underweighted The Bleeding Benefit And The Real-World Patient Story
One reason the reaction feels incomplete is that the bleeding story is not some minor detail. It is central to the entire value proposition.
Watchman reduced non-procedural bleeding meaningfully, and management emphasized that this benefit holds even when procedural risks are included. That matters in a population where long-term bleeding risk is a real concern.
The real-world debate is not whether blood thinners work. It is whether patients want to remain on them for life when an alternative exists.
The entire commercial opportunity rests on shifting Watchman from a second-line option to a first-line choice.
There is also a real-world wrinkle that likely did not get priced properly. Trial adherence to blood thinners was unusually high, much higher than what physicians typically see outside a controlled setting.
In reality, long-term adherence is weaker. That changes how outcomes play out over time and strengthens the case for a one-time procedural solution.
This does not erase the stroke concern. But it does make the broader value proposition more balanced than the stock reaction suggested.
The Bigger Debate Is No Longer About Whether Watchman Works, But How Fast The Market Opens Up
The most important takeaway is that Boston Scientific likely strengthened the long-term case, even if it did not trigger immediate acceleration.
The company still sees the addressable market expanding from about 5 million to 20 million patients over time. But that expansion was never going to be unlocked by one dataset alone.
It depends on guidelines, reimbursement, physician adoption, and regulatory updates. Those are slow-moving levers, not instant catalysts.
This is where the 9% drop becomes interesting. The stock traded as though the opportunity had weakened, while analysts suggested the opportunity remains intact, just on a longer timeline.
Those are very different outcomes. One implies structural damage, the other implies expectation reset.
If that framing is right, the selloff reflects compression in expectations rather than destruction of value. And that shifts the debate from “what happened in the trial?” to “how much was already priced in?”
Final Thoughts
The bullish case still rests on Watchman’s bleeding advantage, first-line potential, and large future market, while the cautious case rests on the ischemic stroke imbalance and a slower adoption curve.
Valuation now looks materially less stretched than before. The stock sits around 18.5x LTM EV/EBITDA and 32.4x LTM P/E, compared to significantly higher levels in prior quarters.
That is more reasonable than before, but not obviously cheap. The company now needs execution and adoption progress, not just clinical validation, to support the next phase of its story.
Disclaimer: We do not hold any positions in the above stock(s). Read our full disclaimer here.
